ObvioHealth raises $3 million to facilitate mobile clinical trials
Date: 2018-03-25   Author: Paroma Bhattacharya  Category: #news

ObvioHealth, one of the notable “site-less” clinical trial companies of Singapore, recently announced raising $3 million in a Series A funding round. Reportedly, the financing will help the firm in supporting its operational team and present growth requirements. The funding round has been led by TSK I, a venture fund that chiefly focuses on life science and healthcare initiative financing.

As per reliable sources, ObvioHealth will be digitizing the entire process in order to comply with Food and Drug Administration (FDA) Good Clinical Practices. The company has also been focusing on facilitating cost efficient and faster clinical trials.

For the record, ObvioHealth’s proprietary software, ClaimIt, supports interventional and observational studies, allowing real-time interactions with subjects, as well as integration with smartphones and connected devices.

CEO of ObvioHealth, Bryan Silverman reportedly said that CliamIt has become a go-to platform for sponsors who value cost and time savings that online clinical trials through ClaimIt can offer. He went on to add that ClaimIt is generating significant traction through its digital platform in therapeutic areas as it facilitates expensive and complex studies within the traditional model.

The venture fund TKS I has been formed by the SPRIM Ventures, the VC arm of SPRIM and Tikehau Investment Management. SPRIM is a global innovation firm focused on healthcare while Tikehau Investment Management is an investment and asset management group which manages assets that surpass US$17 billion in value.

In a statement, Tikehau IM Chairman Bruno de Pampelonne reportedly said that technology is to be thanked for the disruption caused in clinical trial industry. He further added that the firm is excited to receive this opportunity to support the growth of ObvioHelath with the Series A financing round. He expressed belief that since ObvioHelath is led by a team of experienced professionals with a detailed vision, the firm would soon become one of the global leaders in mobile clinical trial.



About Author


Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from...

Read More

More from Paroma


Post Recommendents

Humana & PE firm consortium to buy Curo Health for $1.4 billion
Author: Paroma Bhattacharya

A consortium consisting of the notable U.S. health insurer Humana along with PE firms Welsh, Carson, Anderson & Stowe and TPG Capital announced that they have reached an agreement to acquire Curo Health Services, a...


Bill 13 to ensure energy retailers attend to billing complaints pronto
Author: Paroma Bhattacharya

Under a new bill introduced in Alberta, Canada, electricity and gas retailers in the state will be liable to pay hefty fines if they fail to settle customer billing complaints. Bill 13 now gives the Alberta Utilities C...


Evonik launches RESOMER composite polymers for bone fixation devices
Author: Ojaswita Kutepatil

Evonik, one of the leading biodegradable bone graft polymers industry majors, has recently announced the launch of its very first product grade from a brand-new product line of RESOMER Composite polymers.